Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung
- PMID: 15557619
- PMCID: PMC529154
- DOI: 10.1128/IAI.72.12.6969-6977.2004
Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung
Abstract
Pseudomonas aeruginosa uses a type III secretion system to promote development of severe disease, particularly in patients with impaired immune defenses. While the biochemical and enzymatic functions of ExoU, ExoS, and ExoT, three effector proteins secreted by this system, are well defined, the relative roles of each protein in the pathogenesis of acute infections is not clearly understood. Since ExoU and ExoS are usually not secreted by the same strain, it has been difficult to directly compare the effects of these proteins during infection. In the work described here, several isogenic mutants of a bacterial strain that naturally secretes ExoU, ExoS, and ExoT were generated to carefully evaluate the relative contribution of each effector protein to pathogenesis in a mouse model of acute pneumonia. Measurements of mortality, bacterial persistence in the lung, and dissemination indicated that secretion of ExoU had the greatest impact on virulence while secretion of ExoS had an intermediate effect and ExoT had a minor effect. It is of note that these results conclusively show for the first time that ExoS is a virulence factor. Infection with isogenic mutants secreting wild-type ExoS, ExoS defective in GTPase-activating protein (GAP) activity, or ExoS defective in ADP-ribosyltransferase activity demonstrated that the virulence of ExoS was largely dependent on its ADP-ribosyltransferase activity. The GAP activity of this protein had only a minor effect in vivo. The relative virulence associated with each of these type III effector proteins may have important prognostic implications for patients infected with P. aeruginosa.
Figures





Similar articles
-
Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection.Infect Immun. 2005 Mar;73(3):1695-705. doi: 10.1128/IAI.73.3.1695-1705.2005. Infect Immun. 2005. PMID: 15731070 Free PMC article.
-
The ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of Pseudomonas aeruginosa during pneumonia.mBio. 2014 Jun 10;5(3):e01080-14. doi: 10.1128/mBio.01080-14. mBio. 2014. PMID: 24917597 Free PMC article.
-
ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.Mol Microbiol. 1997 Aug;25(3):547-57. doi: 10.1046/j.1365-2958.1997.4891851.x. Mol Microbiol. 1997. PMID: 9302017
-
Role of Pseudomonas aeruginosa type III effectors in disease.Curr Opin Microbiol. 2009 Feb;12(1):61-6. doi: 10.1016/j.mib.2008.12.007. Epub 2009 Jan 23. Curr Opin Microbiol. 2009. PMID: 19168385 Review.
-
Pseudomonas aeruginosa ExoS and ExoT.Rev Physiol Biochem Pharmacol. 2004;152:79-92. doi: 10.1007/s10254-004-0031-7. Epub 2004 Aug 24. Rev Physiol Biochem Pharmacol. 2004. PMID: 15375697 Review.
Cited by
-
High pyocyanin production and non-motility of Pseudomonas aeruginosa isolates are correlated with septic shock or death in bacteremic patients.PLoS One. 2021 Jun 11;16(6):e0253259. doi: 10.1371/journal.pone.0253259. eCollection 2021. PLoS One. 2021. PMID: 34115807 Free PMC article.
-
A Structure-Function-Inhibition Analysis of the Pseudomonas aeruginosa Type III Secretion Needle Protein PscF.J Bacteriol. 2020 Aug 25;202(18):e00055-20. doi: 10.1128/JB.00055-20. Print 2020 Aug 25. J Bacteriol. 2020. PMID: 32601072 Free PMC article.
-
Compendium-Wide Analysis of Pseudomonas aeruginosa Core and Accessory Genes Reveals Transcriptional Patterns across Strains PAO1 and PA14.mSystems. 2023 Feb 23;8(1):e0034222. doi: 10.1128/msystems.00342-22. Epub 2022 Dec 21. mSystems. 2023. PMID: 36541762 Free PMC article.
-
Characterization of Virulence Genes Associated with Type III Secretion System and Biofilm Formation in Pseudomonas aeruginosa Clinical Isolates.Curr Microbiol. 2023 Oct 25;80(12):389. doi: 10.1007/s00284-023-03498-4. Curr Microbiol. 2023. PMID: 37880467
-
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.Infect Drug Resist. 2013 Nov 29;6:215-23. doi: 10.2147/IDR.S36140. Infect Drug Resist. 2013. PMID: 24348053 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous